Cda-2, A Urinary Preparation, Inhibits Lung Cancer Development Through The Suppression Of Nf-Kappab Activation In Myeloid Cell
Xuan Wang,Cui-Min Jiang,Hai-Ying Wan,Jun-Lu Wu,Wen-Qiang Quan,Robert Bals,Kai-Yin Wu,Dong Li
DOI: https://doi.org/10.1371/journal.pone.0052117
IF: 3.7
2012-01-01
PLoS ONE
Abstract:CDA-2 (cell differentiation agent 2), a urinary preparation, has potent anti-proliferative and pro-apoptotic properties in cancer cells. However, the mechanisms of tumor inhibitory action of CDA-2 are far from clear, and especially there was no report on lung cancer. Here we demonstrate that CDA-2 and its main component phenylacetylglutamine (PG) reduce the metastatic lung tumor growth, and increases survival time after inoculation with Lewis lung carcinoma (LLC) cells in a dose-dependent manner in C57BL6 mice. Proliferative program analysis in cancer cells revealed a fundamental impact of CDA-2 and PG on proliferation and apoptosis, including Bcl-2, Bcl-XL, cIAP1, Survivin, PCNA, Ki-67 proteins and TUNEL assays. CDA-2 and PG significantly reduced NF-kappa B DNA-binding activity in lung cancer cells and in alveolar macrophages of tumor bearing mice and especially decreased the release of inflammatory factors including TNF alpha, IL-6, and KC. Furthermore, CDA-2 and PG decrease the expressions of TLR2, TLR6, and CD14, but not TLR1, TLR3, TLR4, and TLR9 in bone-marrow-derived macrophages (BMDM) of mice stimulated by LLC-conditioned medium (LLC-CM). Over-expressing TLR2 in BMDM prevented CDA-2 and PG from inhibiting NF-kappa B activation, as well as induction of TNF alpha and IL-6. TLR2: TLR6 complexes mediate the effect of NF-kappa B inactivation by CDA-2. In conclusion, CDA-2 potently inhibits lung tumor development by reduction of the inflammation in lung through suppression of NF-kappa B activation in myeloid cells, associating with modulation of TLR2 signaling.